TYLER, Texas (KETK)-- Pharmaceutical companies Moderna and Merck have revealed an experimental vaccine that shows signs of preventing melanoma from returning in patients. The personalized vaccine uses genetic material from a patient's own cancer to train the immune system to target the disease bette…
KETK Tyler's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.
Developments in this update
3 dated developments, oldest first, newest marked. Each is named by one outlet's own headline; open its reports to see every outlet that covered it.
Moderna, Merck breakthrough could usher in cancer vaccines
Headline from Omaha World-Herald ·
Names this update
Experimental vaccine could prevent melanoma cancer from returning
Headline from KETK Tyler ·
Newest
Cancer vaccine breakthrough 'a monumental leap forward'
Interim results from the trial show that the vaccine-drug combination appeared to increase the time before cancer returned in the high-risk patients, the companies said.
Moderna and Merck said on Wednesday that a personalized mRNA cancer vaccine reduced the risk of recurrence and spread of melanoma in a late-stage trial, a major success in a new field of cancer treatment that sent Moderna’s shares surging…
U.S. pharmaceutical firms Merck and Moderna announced Wednesday encouraging results from a trial of their experimental vaccine against melanoma, potentially clearing the way for approval.
Moderna and Merck announced today that their personalized mRNA-based cancer vaccine, combined with Merck’s immunotherapy medication Keytruda, met initial goals in a late-stage trial. The ongoing mRNA cancer vaccine study involves 1,137 patients with high-risk melanoma that has been surgically remove…
Stock prices for the American vaccine manufacturer Moderna more than doubled on Wednesday after the company reported successful results from its messenger RNA melanoma cancer vaccine. The mRNA shot, in combination with Merck’s immunotherapy drug Keytruda, met critical benchmarks in a global late-sta…
An experimental personalized mRNA-based cancer vaccine from Merck and Moderna was successful at preventing melanoma from returning or spreading in a late-stage trial of high risk patients, the companies announced Wednesday.
Moderna shares more than doubled after announcing initial results from a study of an experimental cancer treatment. Moderna and Merck are developing an mRNA-based cancer vaccine designed to be tailored to individual patients based on unique mutations within their tumors.
Moderna is up 130% today with success of a phase 3 trial on AI Assisted personalized MRNA cancer treatment. Major Progress to Curing Cancer From Moderna Melanoma Vaccine. Phase 2 showed 50-60% reduction in cancer deaths, but pathway to personalized AI cancer treatments.
An experimental mRNA vaccine allowed people with high-risk melanoma to live longer, cancer-free, in a large, closely watched trial, pharmaceutical companies Moderna and Merck announced today.
Pharmaceutical giants Moderna and Merck said that an experimental vaccine treatment has shown signs of preventing cancer from returning or spreading in a study of high-risk melanoma patients. NBC News health reporter Aria Bendix explains what happens next.
Merck and Moderna announced Wednesday that a personalized mRNA-based cancer vaccine succeeded in a large, late-stage trial among high-risk patients with melanoma.
By Meg Tirrell, Jamie Gumbrecht, and Reuters (CNN) — A personalized mRNA cancer vaccine combined with the immunotherapy Keytruda succeeded in a late-stage trial for the deadly skin cancer melanoma, its makers said Wednesday, potentially opening up a new way of treating the disease.
